



hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 7, 2007

Signature: Elaine Leachy
(Elaine Leachy)

Docket No.: ALXN-P01-114
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bell et al.

Application No.: 10/771,552

Confirmation No.: 6183

Filed: February 3, 2004

Art Unit: 1644

For: METHOD OF TREATING HEMOLYTIC
DISEASE

Examiner: F. P. Vandervegt

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

05/10/2007 CCHAU1 00000070 181945 10771552

01 FC:1806 10511694_1 180.00 DA

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ALXN-P01-114. A duplicate copy of this paper is enclosed.

Dated: 5/7/2007

Respectfully submitted, Reg No. 46,778

By 
for Amita Varnia, Esq.

Registration No.: 43,221
FISH & NEAVE IP GROUP, ROPES & GRAY
LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/771,552
				Filing Date	February 3, 2004
				First Named Inventor	Leonard Bell
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
Sheet	1	of	3	Attorney Docket Number	ALXN-P01-114

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AD	US-6,255,245	03-12-2002	Evans et al.	
	AE	US-20030049683	03-13-2003	Bowdish et al.	
	AF	US-5,660,825	08-26-1997	Sims et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	CE	"Alexion Reports Presentation of Membranous Nephritis Clinical Trials"; [online]; Alexion Pharmaceuticals: News; [Retrieved on 2003-06-17]. Retrived from the Internet: http://www.alexionpharm.com/news/sub_press.cfm?prid=241&selectyear=2002 .				
	CF	Alexion Phamaceuticles: Complement Inhibitors; [online]; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.alexionpharm.com/techplat/complement.cfm .				
	CG	"Alexion Pharmaceuticlasl Signs Agreement with Lonza Biologics for Commercial Manufacturing"; [online]; Alexion Pharmaceuticls Inc.; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.noonanrusso.com/news/view_newsitem.aspx?itemID=394 .				
	CH	"Alexion Announces Results of Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria Presented at the American Society of Hematology Annual Meeting"; [online]; Alexion Pharmaceuticals, Inc.; [Retrieved on 2003-06-17]; Retrieved from the Internet: http://www.noonanrusso.com/news/view_newsitem.aspx?itemID=382 .				
	CI	"Alexion announces presentation of preliminary Results from Phase I Pilot Study of Eculizumab Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria"; [online]; Alexion Pharmaceuticals: News; [Retrieved on 2003-06-18]. Retrieved from the Internet: http://www.alexionpharmaceuticals.com/news/sub_press.cfm?prid=242&selectyear=2002 .				
	CJ	Araten, et al., "High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria," Thromb Haemost 2005; 93:88-91.				
	CK	Audebert et al., "Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria," J. Neurol 2005 252 1379-2565 (2005).				
	CL	Fitch et al., "Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass," Circulation 100(25):2499-2506 (1999)				
	CM	"Genes and Disease"; [online]; Paroxysmal nocturnal gemoglobinuria; [Retrived on 2003-06017]. Retrived from the Internet: http://www.ncbi.nlm.nih.gov/disease/PNH.html				
Examiner Signature		Date Considered				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/771,552
				Filing Date	February 3, 2004
				First Named Inventor	Leonard Bell
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
Sheet	2	of	3	Attorney Docket Number	ALXN-P01-114

	CN	Hall et al., "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)," <u>Blood</u> 2003 102 3587-91.	
	CO	Hill et al., "Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria," <u>Haematologica</u> 90(12): Abstract #ECR40	
	CP	Hill et al., "Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy," <u>Blood</u> , 104:Abstract 2823 (2004) with ASH poster final 2004.ppt. ASH poster final 2004.ppt.	
	CQ	Hill et al., "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria," <u>Blood</u> 106 2559-2565 (2005).	
	CR	Hillmen et al., "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria," <u>N Engl J Med</u> 350 552-559 (2004).	
	CS	Hillmen et al., "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria," <u>N Engl J Med</u> 355 1233-1243 (2006).	
	CT	Inoue N. et al., "Molecular genetics of paroxysmal nocturnal hemoglobinuria," <u>Int J. Hematol.</u> 2003 Feb;77(2):107-112.	
	CU	Kaplan, M. "Eculizumab (Alexion)" <u>Curr Opin Investig Drugs</u> , 2002 Jul;2(7):1017-23.	
	CV	Kinoshita, "Molecular pathogenesis of Paroxysmal Nocturnal Haemoglobinuria,"	
	CW	MacNeil, J.S., "Eculizumab could be paroxysmal nocturnal hemoglobinuria breakthrough,"; MacNeil, J.S.; [online]; Medscape from WebMD; [Retrieved on 2003-06-17. Retrieved from the Internet: http://www.medscape.com/viewarticle/446336 .	
	CX	Mortazavi et al., "The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot," <u>Blood</u> 101 2833-2841 (2003).	
	CY	Moyo et al., "Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays," <u>British J Haematology</u> 126, 133-138 (2004).	
	CZ	"Paroxysmal nocturnal hemoglobinuria, included; PNH, included phosphatidylinositol glycan, class A, pseudogene 1, included; pigap1, included piga-related processed gene, included [online]. OMIM-Online Medelian Inheritance in Man; John Hopkins University; [Retrieved on 2003-06-18]. Retrieved from the Internet: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=OMIM&dopt=detailed...	
	CA1	Richards et al., "Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria," <u>Blood</u> , 104:Abstract 172 (2004).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--